Regulatory Articles

  1. Barcoding Standards And The Search For A UDI “Easy Button”

    As the FDA’s next deadline for the unique device identification (UDI) of Class II devices draws closer, medical device manufacturing companies are looking to further their UDI implementation, whether they are well on their way to success or they haven’t even started. Barcoding, or identifying products via GS1 regulatory standards, is essential for companies wishing to be up to date on UDI implementation. Unfortunately, companies may be delaying UDI implementation because they view the new regulations as something an organization can address quickly. This is not the case. This article discusses the importance of viewing UDI implementation as process that encompasses the entire company rather than just as a “quick fix.”  

  2. 7 Considerations For More Effective Medical Device Labeling And Overlays

    Labels often are an afterthought, because they don’t directly affect the capabilities of a medical device. However, they certainly affect the functionality of the device and users’ ability to effectively utilize all of its features. Consider these factors — and their importance — as you design your medical device overlay or inventory stickers.

  3. 3 Regulatory Guidelines For Navigating China’s Drug Delivery And Medical Device Markets

    Global spending on healthcare medicines is expected to reach $1.3 trillion by end of year 2018. While many of these medicines may be developed in the traditional dosage forms, companies are increasingly developing more and more drug delivery devices, in order to deliver patient convenience, more effective routes of administration through targeted therapies, and value to the global payors. As the world’s second largest medical device market, China offers a significant opportunity for drug delivery companies to expand their global footprint in Asia.

  4. The Building Blocks Of A Successful Drug Delivery Device

    Creating a successful drug delivery device requires the seamless integration of the biological or pharmaceutical regulatory requirements with the device regulatory requirements. There are several factors that need to be considered in order to do this, all while ensuring the patient is kept at the center of the design.

  5. The First Step To Navigating Your Combination Product’s Regulatory Pathway: PMOA

    The drug-device combination product market is growing at a rapid pace. By 2019 it is expected that the global market for drug device combination products will reach $115.1 billion. This is nearly double its worth from $66 billion back in 2012. This burgeoning market will likely bring in a flood of product submission applications to the FDA at a time when resources are already strained.

  6. Assessing The FDA’s Cybersecurity Guidelines For Medical Device Manufacturers

    In practically all matters of cybersecurity within the health sector, the United States Food and Drug Administration (FDA) seems to be in a constant state of offering subtle suggestions where regulatory enforcement is needed. The argument against enforcing cybersecurity standards typically centers on the idea that a regulatory presence stifles innovation. Due to the industry’s continuous lack of cybersecurity hygiene, malicious electronic health record (EHR) exfiltration and vulnerabilities in healthcare’s Internet of Things (IoT) continue to be a profitable priority target for hackers.

  7. 6 Guidelines To Follow When Developing Combination Products

    While the development of a combination product comes with significant patient benefits through technology and molecule innovation, that reward can be offset by the range of regulatory complexity and uncertainty encountered with bringing a product to market, in addition to any post-marketing activities.

  8. Two Essential Steps To Protecting Your Global Supply Chain From UDI Disruption

    For most medical device companies, compliance with the Class III FDA UDI final rule already has been addressed, and most project stakeholders probably have started to develop a compliance strategy for FDA UDI Class II. What UDI-impacted stakeholders may not be considering is how FDA UDI could impact their company’s global inventory management strategy. In this article, we provide two steps companies should take to ensure their global supply chain maintains continuous flow of product. 

  9. Medical Device Registries: Recommendations For Advancing Safety And Public Health

    Recent high-profile failures of medical device technologies, including metal-on-metal hips and implantable cardiac defibrillators, are a reminder that this country lacks a robust system for assessing the safety and effectiveness of medical devices once they enter the market.

  10. Cleanliness Validation For Medical Devices

    Residues on the surface of medical devices can cause implant failure and poor device performance. The main source of these residues is from materials used in the manufacture of the device, although contamination during the storage, cleaning and handling of the device is also known to occur.By Chris Pickles, Ph.D.